Joe Duarte

Dr. Joe Duarte has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

I am recommending the purchase of put options on Anthem Inc. (NYSE: ANTM), a leading U.S. health insurer which offers Blue Cross/Blue Shield plans in fourteen states.  The company’s shares have been slowly falling of late and are reaching an attractive price area for this strategy.  I’ll tell you why… Read More

I have been increasingly concerned about the action in the overall stock market for some time, and the action on yesterday (8/24) afternoon and this morning suggested that it’s time to buy some portfolio protection.  So I am recommending the purchase of the ProShares Ultrashort ETF (BIS) as a hedge for a diversified… Read More

Today, I am (1) closing out a bonus position I recommended earlier this year in Celldex Therapeutics (Nasdaq: CLDX); (2) increasing the buy limit on my latest pick Diebold Nixdorf (NYSE: DBD); and, (3) changing my rating on Ambarella (Nasdaq: AMBA) to ‘Hold’. I explain the rationale for these moves in… Read More

I am raising the rating on Medidata Solutions (NSDQ: MDSO), the leading cloud based software platform for biotech research management to Buy from Hold.  I recommended the stock in March 2015 and so far it has delivered a 51% price increase.  But recent price behavior suggests that it’s poised for… Read More

Seres Therapeutics (Nasdaq: MCRB), a research stage biotech company seeking to use the human microbiome to treat gut-related illnesses, expanded its losses in its most recent quarter.  The company reported a loss of $27.8 million, or 70 cents per share, and $3 million in revenues for the quarter as it… Read More

I am increasing the Buy limit on Opko Health (OPK), a diversified health care company focused on renal diseases and precise laboratory testing, from to $11 to $12 as the company beat its quarterly earnings expectation and gave upbeat guidance on its August 8 earnings release.  I am leaving the… Read More

The health care sector is about to get bumpy with some stocks flourishing while others fall on hard times.  Just in the past week we saw a totally different set of reactions to earnings reports as shares of Cerus Corp. (Nasdaq: CERS) sidestepped bad news and rallied while Emergent BioSolutions… Read More

I am recommending the sale of Novo Nordisk NYSE: (NVO) and Emergent BioSolutions (NYSE: EBS).  Both companies failed to meet expectations and are likely to run into further headwinds as the biotech and healthcare dynamic changes gears and price cutting pressure in the U.S. starts to gather steam.Emergent BioSolutions Inc. Read More